Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Desarrollo de un nuevo medicamento para el tratamiento de la diabetes mediante la proteína quinasa MST-1


Oferta Tecnológica
El centro de interacciones biomoleculares de una universidad alemana busca una compañía farmacéutica para desarrollar un medicamento contra la diabetes. Los investigadores han identificado la proteína quinasa MST-1, responsable de la muerte de células productoras de insulina debido a la apoptosis (muerte celular programada) y a la aparición de la diabetes. La proteína sirve tanto para la diabetes tipo 1 como para la diabetes tipo 2, dependiendo de la edad y obesidad. El objetivo es establecer acuerdos de licencia, investigación o cooperación técnica.


Partner sought for new drug development for diabetes therapy by means of protein kinase MST-1
The centre for biomolecular interactions of a German university is looking for a partner for diabetes drug development by means of a license agreement, research cooperation or technical cooperation agreement.
The Centre for Biomolecular Interactions of a German university is looking for a partner for diabetes drug development.

Diabetes mellitus is a metabolic disorder which causes increased blood sugar levels. The disease destroys the insulin-producing cells of the pancreas, the beta cells of the islets of Langerhans. This causes a lack of the blood sugar-reducing hormone insulin, resulting in a chronically increased blood sugar level. More than 7 million people are affected by this disease in Germany.

Researchers of molecular diabetology of a German University have now identified a key protein, protein kinase MST-1, which is responsible for the death of these insulin-producing cells due to apoptosis (programmed cell death) and thus for the formation of the diabetes disease. This is valid for both forms of diabetes, namely the autoimmune type 1 and type 2, which depends on age and obesity.

The scientists are carrying out intensive research on the involvement of the protein kinase MST-1 in the apoptopic processes in the beta cells. MST-1 plays a key role in the stimulation of specific signal path cascades. It was possible to demonstrate in experiments that MST-1 inhibition can prevent the formation of both type 1 and type 2 diabetes. Influencing the protein kinase MST-1 is therefore a promising therapeutic objective for the development of suitable therapies to treat both forms of diabetes.

A pharmaceutical company in drug development for the therapy of type 1 and 2 diabetes is being sought. Collaboration can be arranged by license agreement, research cooperation agreement or technical cooperation agreement, depending on the contribution of the partner.

The desired outcome of a partnership is drug development that can contribute to a specific therapy for diabetes. The patent offers potential for drug development that will help to treat and to prevent the diabetes disease worldwide.
Advantages and Innovations:
Protein kinase MST-1, has been identified to be responsible for the death of insulin producing cells due to apoptosis (programmed cell deaht) and thus for the formation of the diabetes disease.

It was possible to demonstrate that the targeted inhibition of the protein was able to maintain the secretions of insulin and prevent the disease from progressing.

Influencing the protein kinase MST-1 is therefore a new promising therapeutic objective for the development of suitable therapies to treat both forms of diabetes type 1 and 2.

- Clarification of the role of MST-1 in the formation of the apoptosis provides a new aim for taking an effective therapeutic approach to diabetes.
- Protection of the beta cells by inhibiting the MST-1 prevents diabetes from progressing or from arising altogether.
- The inhibition of MST-1 results in the prevention of hyperglycemia and in an improved glucose tolerance. It was possible for the first time to demonstrate this in a mouse model.
- The treatment of diabetes and its sequelae (neural injuries, circulatory disorders in the legs and feet, eye and kidney damage) lead to enormous costs for the health care system which could be reduced via early treatment and the possibility of curing the disease.
- According to the Diabetes Atlas of the International Diabetes Federation (IDF), approx. 7 million people (with a rising tendency) affected by diabetes live in Germany, 56 million in Europe, 382 million worldwide. Therefore there is major demand for suitable and efficient therapy options.
- Efficient solutions and innovative approaches to curing diabetes are currently the subject of interest of many pharmaceutical companies.
Stage of Development:
Under development/lab tested
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A worldwide patent (PCT) is applied for but not yet granted, countries are not yet selected.

Partner sought

Type and Role of Partner Sought:
- Type of partner sought: Pharmaceutical company

- Specific area of activity of the partner: Drug Development, Diabetes

- Task to be performed by the partner sought: Drug development based on the patent, cooperation in furthermore animal experiments, financial support


Type and Size of Client:
Already Engaged in Trans-National Cooperation:
Languages Spoken:


Restrict dissemination to specific countries:
Albania, Armenia, Austria, Belgium, Bosnia And Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Croatia, Cyprus, Czech_Republic, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Korea, Republic Of, Latvia, Lithuania, Luxembourg, Macedonia, The Former Yugoslav Republic Of, Malta, Mexico, Moldova, Republic Of, Montenegro, Morocco, Netherlands, Norway, Poland, Portugal, Republic of Serbia, Romania, Russian Federation, Slovakia, Slovenia, Spain, Sweden, Switzerland, Tunisia, Turkey, Ukraine, United Kingdom, United States


Technology Keywords:
06002002 Biología celular y molecular
03004007 Fármacos
06001015 Productos farmacéuticos / medicamentos